Your browser doesn't support javascript.
loading
A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia.
Saxena, Kapil; Herbrich, Shelley M; Pemmaraju, Naveen; Kadia, Tapan M; DiNardo, Courtney D; Borthakur, Gautam; Pierce, Sherry A; Jabbour, Elias; Wang, Sa A; Bueso-Ramos, Carlos; Loghavi, Sanam; Tang, Guillin; Cheung, Cora M; Alexander, Lynette; Kornblau, Steven; Andreeff, Michael; Garcia-Manero, Guillermo; Ravandi, Farhad; Konopleva, Marina Y; Daver, Naval.
Afiliação
  • Saxena K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Herbrich SM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Pierce SA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wang SA; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Bueso-Ramos C; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Tang G; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Cheung CM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Alexander L; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kornblau S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Konopleva MY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer ; 127(20): 3761-3771, 2021 10 15.
Article em En | MEDLINE | ID: mdl-34171128
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Azacitidina / Leucemia Mieloide Aguda Limite: Adult / Aged / Aged80 / Humans / Middle aged Idioma: En Revista: Cancer Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Azacitidina / Leucemia Mieloide Aguda Limite: Adult / Aged / Aged80 / Humans / Middle aged Idioma: En Revista: Cancer Ano de publicação: 2021 Tipo de documento: Article